SS Innovations Builds Telerobotic Surgery Position as Remote Procedures Gain Ground

Telerobotic surgery is transitioning from experimental demonstrations to broader clinical and regulatory development, and SS Innovations International (NASDAQ: SSII) is positioning itself at the center of that shift. The company’s founder and CEO, cardiac surgeon Dr. Sudhir Srivastava, recently told MedTech Dive that robotic surgery is inherently a form of teleoperation, and that the key technical challenge is determining how much distance can be introduced without compromising responsiveness. That question is becoming more pressing as remote procedures gain traction worldwide.

According to a recent MedTech Dive report, “Telerobotic surgery is advancing around the world. Will the US embrace it?,” the technology’s development raises important regulatory and infrastructure considerations. The article highlighted SS Innovations alongside larger medical-device companies and emerging robotics developers (https://ibn.fm/4ZLvL). For SS Innovations, the discussion comes as its SSi Mantra system accumulates real-world experience in telesurgery.

As of September 28, 2026, the company reported 195 robotic telesurgeries using the SSi Mantra system, including cardiac procedures and long-distance operations. The installed base reached 244 SSi Mantra systems, up 45% from the end of 2025, while cumulative procedures totaled 14,503. The system has expanded into 12 countries, with recent cardiac-surgery programs launched in Colombia and Sri Lanka, and a new program established at HCG Hospital in Ahmedabad. These figures underscore the growing adoption of SS Innovations’ technology and its potential to address unmet needs in remote and underserved regions.

The company is currently pursuing U.S. FDA clearance and European Union CE marking as it seeks to expand into additional international markets. Securing these regulatory approvals would be a significant milestone, potentially opening the door to the world’s largest healthcare markets and accelerating the adoption of telerobotic surgery. The outcomes of these regulatory processes will be closely watched by investors and industry participants alike.

The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII. As telerobotic surgery gains ground, SS Innovations’ progress in clinical adoption and regulatory clearance will be critical in determining whether it can capture a leading share of this emerging market. The company’s ability to demonstrate safety and efficacy across diverse geographies will likely influence both physician adoption and payer coverage.

For more information about SS Innovations and its telerobotic surgery initiatives, visit Read More>>. The broader investment community can also follow developments through MissionIR, a specialized communications platform that is part of the Dynamic Brand Portfolio @ IBN. Through its network, MissionIR provides access to wire solutions via InvestorWire and editorial syndication to 5,000+ outlets, among other services. These channels help ensure that significant developments in telerobotic surgery reach a wide audience of investors and industry stakeholders.

As remote procedures continue to gain ground, SS Innovations’ growing procedure volume and international expansion highlight the commercial potential of telerobotic surgery. The company’s pursuit of FDA and CE mark approvals will be pivotal in bringing this technology to more patients and clinicians globally.